IMMUNETHEP
Biotech start-up company that is developing broad coverage anti-bacterial immunotherapies .
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
$2.0m | Support Program | ||
| Total Funding | 000k | ||
| EUR | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 100 % | (16 %) | 6 % | (93 %) | 6766 % | 90 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (187 %) | (179 %) | (303 %) | (246 %) | (5924 %) | (83 %) | 32 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (193 %) | (147 %) | (255 %) | (205 %) | (4834 %) | (69 %) | 14 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Developer of Innovative immunotherapies targeting the major bacterial threats in Antimicrobial Resistance.
The company is developing preventive and therapeutic broad-coverage anti-bacterial immunotherapies based on discovering a novel mechanism different pathogenic bacteria use to suppress host immune response.
Immunthep's flagship products are a set of preventive vaccines with full serotype coverage for a set of bacteria responsible for over 50% of all bacterial deaths, and without preventive solutions in the market.
The company is also developing monoclonal antibodies as a therapeutic solution for these infections, particularly when vaccination is no longer possible.
Keywords: Antimicrobial Resistance, Bacterial Infection, Immunity Development, Immunotherapy Company, Immunotherapy Product, Vaccines For Infectious Disease, Antibodies.